PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Accordini, S.* ; Corsico, A.G.* ; Braggion, M.* ; Gerbase, M.W.* ; Gislason, D.* ; Gulsvik, A.* ; Heinrich, J. ; Janson, C.* ; Jarvis, D.* ; Jõgi, R.* ; Pin, I.* ; Schoefer, Y. ; Bugiani, M.* ; Cazzoletti, L.* ; Cerveri, I.* ; Marcon, A.* ; de Marco, R.*

The cost of persistent asthma in Europe: An international population-based study in adults.

Int. Arch. Allergy Immunol. 160, 93-101 (2013)
Publ. Version/Full Text Volltext DOI PMC
Closed
Background: This study is aimed at providing a real-world evaluation of the economic cost of persistent asthma among European adults according to the degree of disease control [as defined by the 2006 Global Initiative for Asthma (GINA) guidelines]. Methods: A prevalence-based cost-of-illness study was carried out on 462 patients aged 30-54 years with persistent asthma (according to the 2002 GINA definition), who were identified in general population samples from 11 European countries and examined in clinical settings in the European Community Respiratory Health Survey II between 1999 and 2002. The cost estimates were computed from the societal perspective following the bottom-up approach on the basis of rates, wages and prices in 2004 (obtained at the national level from official sources), and were then converted to the 2010 values. Results: The mean total cost per patient was EUR 1,583 and was largely driven by indirect costs (i.e. lost working days and days with limited, not work-related activities 62.5%). The expected total cost in the population aged 30-54 years of the 11 European countries was EUR 4.3 billion (EUR 19.3 billion when extended to the whole European population aged from 15 to 64 years). The mean total cost per patient ranged from EUR 509 (controlled asthma) to EUR 2,281 (uncontrolled disease). Chronic cough or phlegm and having a high BMI significantly increased the individual total cost. Conclusions: Among European adults, the cost of persistent asthma drastically increases as disease control decreases. Therefore, substantial cost savings could be obtained through the proper management of adult patients in Europe.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
2.248
0.924
148
164
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Asthma ; Cost Of Illness ; Disease Control; Obstructive Pulmonary-disease ; Respiratory-health-survey ; Quality-of-life ; Economic-impact ; Young-adults ; Severity ; Burden ; Illness ; Cohort
Language english
Publication Year 2013
HGF-reported in Year 2013
ISSN (print) / ISBN 1018-2438
e-ISSN 1423-0097
Journal International Archives of Allergy and Immunology
Quellenangaben Volume: 160, Issue: 1, Pages: 93-101 Article Number: , Supplement: ,
Publisher Karger
Publishing Place Basel ; Freiburg [Breisgau] ; Paris ; London ; New York ; Bangalore ; Bangkok ; Singapore ; Tokyo ; Sydney
Reviewing status Peer reviewed
Institute(s) Institute of Epidemiology (EPI)
POF-Topic(s) 30503 - Chronic Diseases of the Lung and Allergies
Research field(s) Genetics and Epidemiology
PSP Element(s) G-503900-001
PubMed ID 22948386
DOI 10.1159/000338998
WOS ID WOS:000311487100012
Scopus ID 84865593053
Erfassungsdatum 2013-01-01
[➜Report correction]